As global head of product development at Sandoz, a Novartis division, Dr. Deshmukh leads a team of 1000+ associates to carry out integrated product development for pharmaceuticals. He oversees the strategy, performance and capability building for R&D teams including technical, clinical, medical and regulatory domains. Dr. Deshmukh also oversees the product investment strategy as a member of the Sandoz Executive Committee.
In his 20+ years in pharmaceutical R&D he has contributed over fifty lectures/publications, patents and brought to market multiple life saving medicines. He helped pioneer Quality by Design as part of the US FDA鈥檚 pilot program for regulatory approval of Torisel庐. In 2019 his team helped Sandoz become the first multinational Pharma to get approval for a Quality Certificate of Excellence (QCE) generic in China. He is actively shaping in-silico R&D through adoption of modeling, simulation and remote sensing solutions.
Prior to joining Novartis in 2016, Dr. Deshmukh was Senior Vice President of R&D at Sun Pharma and earlier served in roles at Pfizer/Wyeth including as Head of US Materials Science and Senior Director for Technology Operations. His training includes a Ph.D. in 91成人短视频 Engineering as Aristech Foundation Fellow from the University of Pittsburgh. He also holds an MBA with honors from the Wharton School, University of Pennsylvania.